Blood Sugar Control, Not Weight Loss, Reversed Liver Fibrosis Risk in Diabetic Patients

For millions of people living with type 2 diabetes, the liver is a silent casualty. Fat accumulates in the organ, inflammation simmers beneath the surface, and over time scar tissue begins to replace healthy cells, a process known as fibrosis that can ultimately progress to cirrhosis and liver failure. The condition, now formally called metabolic dysfunction-associated steatotic liver disease, or MASLD, is extraordinarily common in diabetic populations, and clinicians have long assumed that the two most obvious metabolic culprits, high blood sugar and excess body weight, work together to drive the scarring. But a new clinical trial from researchers at Tabriz University of Medical Sciences in Iran suggests that when it comes to reversing fibrosis risk, these two targets are not equal partners. In a 24-week intervention study published in BMC Endocrine Disorders, achieving tight glycemic control emerged as the independent predictor of a falling fibrosis risk score, while weight loss, surprisingly, did not.

The study enrolled 50 adults who had both type 2 diabetes and MASLD, and it asked a deceptively simple question: if you push patients toward both an HbA1c below 7 percent and a body-weight reduction of at least 5 percent, which of those achievements actually moves the needle on liver fibrosis risk? To answer it, the team used the FIB-4 index, a widely validated, noninvasive scoring tool that combines a patient’s age with the blood levels of two liver enzymes, aspartate aminotransferase and alanine aminotransferase, along with platelet count. The formula exploits a biological logic: as the liver becomes scarred, enzyme levels rise while platelet counts fall, because advanced fibrosis is often accompanied by portal hypertension that pools platelets in an enlarged spleen. A low FIB-4 score reliably identifies patients at low risk of advanced fibrosis, sparing them from more invasive or expensive assessments such as liver biopsy or transient elastography.

The intervention itself was deliberately multifactorial. Over 24 weeks, participants received structured lifestyle modification alongside optimization of their glucose-lowering medications, with explicit targets of an HbA1c below 7 percent and a weight reduction of 5 percent or more. The researchers measured anthropometric parameters, metabolic markers, liver enzymes, and the FIB-4 index at baseline and again at week 24. The design was a single-arm clinical trial, meaning all participants received the same intervention and there was no separate control group, a limitation the authors acknowledge, but one that still allows rigorous within-patient comparisons of how changes in metabolic health track with changes in fibrosis risk.

The results of the intervention were striking across the board. Average HbA1c fell from 9.04 percent at baseline to 6.77 percent at week 24, a drop of more than two full percentage points that brought the cohort, on average, below the classic 7 percent threshold for good glycemic control. Body weight, waist circumference, blood pressure, and lipid profiles all improved significantly, as did aminotransferase levels, the enzymes that leak into the bloodstream when liver cells are injured. Every one of these changes reached statistical significance at p less than 0.001, indicating that the combined lifestyle and pharmacological strategy had reshaped the participants’ cardiometabolic profile in a matter of months.

More importantly for the liver, the FIB-4 index itself declined substantially. The mean score fell from 1.86 at baseline to 1.35 at week 24, a mean change of minus 0.51 that was highly statistically significant. To put those numbers in clinical context, the proportion of participants classified as low-risk for advanced fibrosis more than doubled, rising from 22 percent at the start of the study to 48 percent at its end. Perhaps most remarkably, no patient remained in the high-risk category by week 24. In a population where diabetes and fatty liver disease conspire to accelerate hepatic scarring, a six-month intervention that effectively emptied the high-risk tier is a result that will command attention from hepatologists and endocrinologists alike.

But the study’s most provocative finding came from its statistical deep dive. When the researchers used multivariable linear regression to identify independent predictors of the week-24 FIB-4 index, adjusting for each participant’s baseline score, a clear hierarchy emerged. Optimal glycemic control, achieved by 68 percent of participants, was independently associated with a lower follow-up FIB-4 index, with a regression coefficient of minus 0.229 and a p-value of 0.021. Optimal anthropometric control, meaning the target weight loss of 5 percent or more, was achieved by only 38 percent of participants, and after adjustment it showed no independent association with the fibrosis score at all, with a coefficient of minus 0.048 and a p-value of 0.562. In other words, once you accounted for blood sugar control, hitting the weight-loss target added no measurable benefit to the fibrosis risk score.

This asymmetry challenges a deeply held intuition. Obesity is a foundational driver of MASLD, and weight loss is universally recommended as first-line therapy for the condition, with guidelines typically calling for reductions of 5 to 10 percent of body weight to improve steatosis and, at higher thresholds, fibrosis. The Tabriz findings do not overturn that framework, but they do complicate it. In patients with type 2 diabetes, the study suggests, hyperglycemia may be the more immediate and more modifiable lever on fibrosis risk, at least over a six-month horizon and at least as measured by the FIB-4 index. The mechanistic logic is plausible: chronic hyperglycemia fuels de novo lipogenesis in hepatocytes, promotes oxidative stress and inflammatory signaling, and accelerates the activation of hepatic stellate cells, the cells responsible for laying down collagen scar tissue. Bringing glucose under control may therefore interrupt the fibrogenic cascade at its metabolic source, even before substantial weight loss occurs.

The authors are careful to frame their conclusions within the limits of the study design. The trial was single-arm, small, and lacked a control group, so improvements in FIB-4 cannot be definitively attributed to the intervention rather than to regression to the mean, placebo effects on lifestyle adherence, or the natural course of the disease. The FIB-4 index, while convenient and well validated as a rule-out tool, is a surrogate measure calculated from routine blood tests and age; it does not directly visualize scar tissue. The authors explicitly call for larger controlled studies with histological or elastography endpoints to confirm that the FIB-4 improvements they observed reflect genuine changes in liver fibrosis rather than shifts in the score’s component variables. Notably, the intervention lowered aminotransferase levels, and since these enzymes are numerators in the FIB-4 formula, part of the score’s decline may reflect reduced liver inflammation rather than reduced fibrosis per se.

There are also practical lessons embedded in the achievement rates. Only 38 percent of participants managed the 5 percent weight-loss target, whereas 68 percent reached optimal glycemic control, a disparity that mirrors the everyday experience of clinicians treating type 2 diabetes. Weight loss is notoriously difficult to achieve and sustain, even with intensive support, while modern glucose-lowering therapy, when systematically optimized, can bring HbA1c down by two percentage points or more in a substantial fraction of patients. If glycemic optimization proves to be the stronger independent determinant of fibrosis-risk reduction, that is arguably good news for clinical practice, because it is the more attainable target. It also raises intriguing questions about the role of newer antidiabetic agents, including GLP-1 receptor agonists, which lower glucose and produce weight loss simultaneously, and whether their celebrated benefits on liver outcomes flow more through glycemic pathways than has been assumed.

For now, the study stands as an early but compelling signal that the two pillars of metabolic care in diabetes are not interchangeable when it comes to the liver. A 24-week program of lifestyle change and medication optimization transformed the fibrosis-risk profile of a cohort of patients with type 2 diabetes and MASLD, moving nearly half of them into the low-risk category and out of the high-risk tier entirely, and the analysis points to blood sugar control as the engine of that transformation. As the global burden of diabetes-linked liver disease continues to climb, the finding adds urgency to a message that endocrinologists have long preached but that has often been overshadowed by the cultural focus on the bathroom scale: for the diabetic liver, the glucose meter may matter most. Confirmation from larger, controlled trials with direct measures of fibrosis will determine whether this signal becomes a guideline-changing insight, but the direction of the evidence is already hard to ignore.

Subject of Research: The effect of glycemic and weight control on liver fibrosis risk in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease

Article Title: The effect of optimal glycemic control and anthropometric control on the FIB-4 index in patients with type 2 diabetes mellitus and metabolic-associated fatty liver disease

Article References: Zolfi-Gol, M., Molani-Gol, R., Sadrazar, A., Karbasi, M., & Malekian, M. (2026). The effect of optimal glycemic control and anthropometric control on the FIB-4 index in patients with type 2 diabetes mellitus and metabolic-associated fatty liver disease. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02617-z

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02617-z

Keywords: type 2 diabetes, MASLD, fatty liver disease, FIB-4 index, liver fibrosis, glycemic control, HbA1c, weight loss, clinical trial, hepatology, endocrinology, liver enzymes